glp-1 obesity drug news updates The race may have a new contender. π Regeneron reported Phase 3 data showing its candidate delivered up to 19.3% weight loss at 48 weeks, approaching the efficacy seen New weight-loss drugs surge in
Description
It has a natural yellow pigment (dye) which also shows as bright yellow fluorescence under UV light.
Women with T2DM have a similarly high risk for pregnancy complications as pregnant women with type 1 diabetes...
The diabetes indication segment accounted for the largest share of the market
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
